Paroxetine

證據等級: L5

預測適應症: 10 個

Paroxetine: From Major Depressive Disorder to Melancholia

One-Sentence Summary

Paroxetine is an established selective serotonin reuptake inhibitor (SSRI) used for depressive and anxiety-spectrum disorders. The TxGNN model’s top-ranked signal (Ohdo syndrome, a rare genetic disorder) is very likely a knowledge-graph artefact with no plausible mechanistic basis. The most clinically credible signal in this evidence pack is Melancholia, supported by 1 completed clinical trial and 20 publications (including multiple RCTs), though this largely reflects recognition of paroxetine’s known antidepressant activity rather than a genuinely novel indication.

Quick Overview

Item	Content
Original Indication	Not formally on record — no ARTG licence text available (drug not marketed in Australia). Established use is Major Depressive Disorder / depressive-spectrum disorders, per the drug’s known SSRI classification cited throughout the literature evidence.
Predicted New Indication	Melancholia
TxGNN Prediction Score	98.74%
Evidence Level	L1
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Note on the top-ranked TxGNN signal: The model’s #1-scoring prediction (Ohdo syndrome and variants, 99.11%) — along with two related entries (blepharophimosis–intellectual disability syndrome, Ohdo type; benign paroxysmal torticollis of infancy) — has zero supporting trials or literature and no plausible mechanistic link (these are rare paediatric genetic/developmental disorders). The evidence pack itself flags these as probable embedding artefacts, possibly driven by lexical similarity between “paroxetine” and “paroxysmal,” or proximity to intellectual-disability/psychiatric nodes in the knowledge graph. This report focuses on Melancholia (rank 2), the highest-ranked prediction with real supporting evidence.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (marked as a data gap). Based on known information from the supporting literature, paroxetine is a selective serotonin reuptake inhibitor (SSRI) — a phenylpiperidine compound that potently and selectively inhibits presynaptic serotonin reuptake with minimal affinity for adrenergic, dopaminergic, histaminergic, or cholinergic receptors.

Melancholia is a historically recognised subtype of severe major depressive disorder (DSM-III melancholic features). The repurposing rationale in this evidence pack states plainly that the SSRI mechanism is “the standard pharmacological basis for major depressive disorder including the melancholic subtype… an extension of an existing approved indication, not a novel repurposing hypothesis.” In other words, this prediction is best understood as TxGNN correctly recognising paroxetine’s core antidepressant activity rather than surfacing an unexpected new use. The clinical value of this evidence pack lies less in “discovering” melancholia as a target and more in confirming that the TxGNN signal, when it aligns with well-characterised pharmacology, tracks real evidence — which is useful context for judging the plausibility of the other, evidence-free predictions in the same output (e.g., Ohdo syndrome).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01916824	Phase 4	Completed	53	Compared decision-making styles and computerised task performance between unmedicated major depressive disorder patients and healthy controls; relevant to melancholic depression populations but not a direct paroxetine efficacy trial (relevance grade B).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1487627	1992	RCT	International Clinical Psychopharmacology	Meta-analysis of 178 paroxetine- vs 66 placebo-treated patients with DSM-III melancholia; paroxetine significantly superior to placebo with a clear dose–response relationship.
8517168	1993	RCT	Acta Psychiatrica Scandinavica	Pooled double-blind, parallel-group trial (paroxetine n=167 vs placebo n=169); paroxetine significantly superior on major efficacy variables from week 2, well tolerated.
10836286	2000	RCT	International Clinical Psychopharmacology	24-week double-blind RCT comparing venlafaxine and paroxetine in major depression/dysthymia outpatients.
11354239	2001	Meta-analysis	International Clinical Psychopharmacology	Meta-analysis of 39 RCTs (paroxetine n=1924 vs TCAs n=1834); comparable efficacy to TCAs including clomipramine, with better tolerability.
8106649	1993	Review	Journal of Clinical Psychopharmacology	Overview of efficacy and safety of paroxetine as a novel SSRI for depression; favourable pharmacokinetic profile (once-daily dosing, no active metabolites).
1464219	1992	Review	Clinical Pharmacy	Comparative review of paroxetine, sertraline, and fluvoxamine covering pharmacology, adverse effects, DDIs, and dosing.
15089103	2004	Review	CNS Drugs	Review of controlled-release paroxetine formulation; consistently superior to placebo across major depressive disorder, social anxiety disorder, and PMDD trials.
1431015	1992	Review	International Clinical Psychopharmacology	Dosage, tolerability, and safety overview; 20 mg/day identified as optimal dose, fewer anticholinergic effects than TCAs.
1531828	1992	Review	The Journal of Clinical Psychiatry	Safety review of 6,705 paroxetine-treated patients; no significant cardiovascular effects, few significant drug interactions.
8784663	1996	Case Report	Journal of Clinical Psychopharmacology	Case report of tardive dyskinesia associated with paroxetine use.

Australia Market Information

Paroxetine has no ARTG entries on record in this evidence pack — the drug is currently listed as not marketed in Australia (0 licences). No product name, dosage form, or approved-indication text is available to tabulate.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. This evidence pack contains no populated warnings, contraindications, or drug interaction data (DDI query returned no results).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Melancholia is supported by L1-level evidence (multiple RCTs plus a completed Phase 4 trial) and a coherent, well-established SSRI mechanism — but it substantially overlaps with paroxetine’s already-known use in major depressive disorder rather than representing a novel repurposing target. Combined with the absence of any Australian market presence or local safety data, guardrails are warranted before any clinical application.

To proceed, the following is needed:

Formal mechanism of action (MOA) documentation from DrugBank or TGA PI
TGA-approved Product Information for warnings, contraindications, and drug interactions
Confirmation of ARTG registration status or an import/access pathway, since the drug is not currently marketed in Australia
Contemporary (post-2010) clinical evidence specific to the melancholic subtype, since most supporting trials/literature date from the 1990s–2000s
A clarified evidence framing distinguishing “existing indication confirmation” (melancholia) from “novel repurposing hypothesis,” since this candidate does not meet the latter bar
Disregard rank 1, 3, and 5 predictions (Ohdo syndrome and variants, blepharophimosis-ID syndrome Ohdo type, benign paroxysmal torticollis of infancy) as likely model artefacts unless independent mechanistic or clinical evidence emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.